CLINICAL TRIALS PROFILE FOR MEVACOR
✉ Email this page to a colleague
All Clinical Trials for MEVACOR
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000512 ↗ | Familial Atherosclerosis Treatment Study | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 1984-01-01 | To compare the effects of two intensive lipid-lowering regimens with conventional therapy on coronary atherosclerosis as assessed by arteriography. |
| NCT00000512 ↗ | Familial Atherosclerosis Treatment Study | Completed | University of Washington | Phase 3 | 1984-01-01 | To compare the effects of two intensive lipid-lowering regimens with conventional therapy on coronary atherosclerosis as assessed by arteriography. |
| NCT00062556 ↗ | Effect of Niacin ER/Lovastatin on Peak Walking Time & Claudication Onset Time in Patients With Intermittent Claudication | Completed | Kos Pharmaceuticals | Phase 3 | 2003-01-01 | The purpose of this study is to evaluate if Niacin ER/Lovastatin, at two different doses, compared to diet control (this group will receive a tablet containing 50 mg. of immediate-release niacin) is a safe and effective medicine in subjects with leg pain caused by a narrowing of their leg arteries, a condition called intermittent claudication. At least 366 subjects with leg pain caused by a narrowing of their leg arteries will participate in this study. Niacin ER/Lovastatin is a combination of two FDA (United States Food and Drug Administration) approved cholesterol modifying medications: Niaspan® (extended-release niacin) and lovastatin, a statin (the same medicine found in Mevacor®). Niacin ER/Lovastatin was approved by the FDA under the name of Advicor® for use in the treatment of elevated cholesterol. The use of Niacin ER/Lovastatin in the treatment of peripheral arterial disease and symptomatic relief of intermittent claudication is considered investigational. An investigational use is one that is not approved by the FDA. |
| NCT00071266 ↗ | The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC | Completed | Kos Pharmaceuticals | Phase 3 | 2003-10-01 | The purpose of this study is to compare the dose response and safety of Niacin ER/Lovastatin, Niaspan® and Lovastatin with each other, in subjects with leg pain caused by a narrowing of their leg arteries. At least 870 subjects, with leg pain caused by a narrowing of their leg arteries will take part in this study. Both Niaspan and lovastatin (Mevacor®) are approved by the United States Food and Drug Administration (FDA) to treat high cholesterol. Niacin ER/Lovastatin (Advicor®), a combination of these two drugs, is also approved by the FDA to treat high cholesterol. The use of Niacin ER/Lovastatin to treat narrowing of leg arteries and relieve "intermittent claudication" (leg pain caused by narrowing of the arteries in the leg) is considered investigational. An investigational use is one that is not approved by the FDA. |
| NCT00243880 ↗ | Neuroprotection With Statin Therapy for Acute Recovery Trial (Neu-START) | Completed | Columbia University | Phase 1 | 2005-09-01 | The purpose of this dose escalation study is to evaluate the use of lovastatin for the treatment of acute ischemic stroke. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MEVACOR
Condition Name
Clinical Trial Locations for MEVACOR
Trials by Country
Clinical Trial Progress for MEVACOR
Clinical Trial Phase
Clinical Trial Sponsors for MEVACOR
Sponsor Name
